To hear about similar clinical trials, please enter your email below
Trial Title:
Identifying Saliva Markers of Patients With Stomach, Colorectal (Including Pre-cancer Polyp) and Pancreatic Cancers
NCT ID:
NCT01675258
Condition:
Gastric Cancer
Colorectal Cancer and Pre-cancer Polyps
Pancreatic Cancer
Conditions: Official terms:
Pancreatic Neoplasms
Polyps
Study type:
Observational
Overall status:
Unknown status
Study design:
Time perspective:
Cross-Sectional
Intervention:
Intervention type:
Other
Intervention name:
Salivary samples
Description:
Each participant will give a sample of saliva through spitting for 10 minutes in a
sterile tube.
Arm group label:
Control
Arm group label:
Study
Other name:
Salivary Analysis
Summary:
Colorectal cancers account for 783,000 new cases and cause 437,000 deaths per year across
the world. Diagnosis in the early stages improves survival rates. Up to now, these
cancers are mostly diagnosed only at later stages of the disease's course through
histoimmune staining and molecular biology processes on the tissues biopsied from the
gastrointestinal system under invasive diagnostic procedures of colonoscopy.
Oral fluid presents a large protein complexity and has been recently used as a diagnostic
biofluid for oral, as well as systematic diseases. Using oral fluid as a bio-marker for
the colorectal cancer can be advantageous as it contains gastrointestinal fluids, in
addition to bacteria and bacteria lysate, which can also serve as a bio-markers' source
for colorectal cancers. Proteomic technologies provide the tools needed to discover and
identify disease-associated biomarkers.
The aim of the present study is to identify salivary bio-markers in patients suffering
from colorectal cancers.
Criteria for eligibility:
Study pop:
Patients identified with gastric, colorectal (including pre-cancer polyps) or pancreatic
cancer
Sampling method:
Probability Sample
Criteria:
Inclusion Criteria:
- Has not yet started treatment for the identified cancer
Exclusion Criteria:
- medically compromised patients
- congenital syndromes
- being treated with radiotherapy or chemotherapy.
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Hadassah Medical Organization
Address:
City:
Jerusalem
Country:
Israel
Contact:
Last name:
Hadas Lemberg, PhD
Phone:
0097226777572
Email:
lhadas@hadassah.org.il
Investigator:
Last name:
Moti Moskovitz, DMD, PhD
Email:
Principal Investigator
Start date:
September 2012
Lead sponsor:
Agency:
Hadassah Medical Organization
Agency class:
Other
Source:
Hadassah Medical Organization
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT01675258
